BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 34789592)

  • 1. Enhancement of interleukin-2 production by bovine peripheral blood mononuclear cells treated with the combination of anti-programmed death-ligand 1 and cytotoxic T lymphocyte antigen 4 chimeric monoclonal antibodies.
    Watari K; Konnai S; Okagawa T; Maekawa N; Sajiki Y; Kato Y; Suzuki Y; Murata S; Ohashi K
    J Vet Med Sci; 2022 Jan; 84(1):6-15. PubMed ID: 34789592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune inhibitory function of bovine CTLA-4 and the effects of its blockade in IFN-γ production.
    Watari K; Konnai S; Maekawa N; Okagawa T; Suzuki Y; Murata S; Ohashi K
    BMC Vet Res; 2019 Oct; 15(1):380. PubMed ID: 31665022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Programmed death-ligand 1 expression in swine chronic infections and enhancement of interleukin-2 production via programmed death-1/programmed death-ligand 1 blockade.
    Ganbaatar O; Konnai S; Okagawa T; Nojima Y; Maekawa N; Ichikawa Y; Kobayashi A; Shibahara T; Yanagawa Y; Higuchi H; Kato Y; Suzuki Y; Murata S; Ohashi K
    Immun Inflamm Dis; 2021 Dec; 9(4):1573-1583. PubMed ID: 34414683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells.
    Tekguc M; Wing JB; Osaki M; Long J; Sakaguchi S
    Proc Natl Acad Sci U S A; 2021 Jul; 118(30):. PubMed ID: 34301886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways.
    Zhao Y; Lee CK; Lin CH; Gassen RB; Xu X; Huang Z; Xiao C; Bonorino C; Lu LF; Bui JD; Hui E
    Immunity; 2019 Dec; 51(6):1059-1073.e9. PubMed ID: 31757674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineering Programmed Death Ligand-1/Cytotoxic T-Lymphocyte-Associated Antigen-4 Dual-Targeting Nanovesicles for Immunosuppressive Therapy in Transplantation.
    Xu Z; Tsai HI; Xiao Y; Wu Y; Su D; Yang M; Zha H; Yan F; Liu X; Cheng F; Chen H
    ACS Nano; 2020 Jul; 14(7):7959-7969. PubMed ID: 32515579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo antivirus activity of an anti-programmed death-ligand 1 (PD-L1) rat-bovine chimeric antibody against bovine leukemia virus infection.
    Nishimori A; Konnai S; Okagawa T; Maekawa N; Ikebuchi R; Goto S; Sajiki Y; Suzuki Y; Kohara J; Ogasawara S; Kato Y; Murata S; Ohashi K
    PLoS One; 2017; 12(4):e0174916. PubMed ID: 28445479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-1 Blockade Restores the Proliferation of Peripheral Blood Lymphocyte and Inhibits Lymphocyte Apoptosis in a BALB/c Mouse Model of CP BVDV Acute Infection.
    Liu Y; Wu C; Chen N; Li Y; Fan C; Zhao S; Bai T; Zhao Z; Chen J; Su S; Zhang Z; Zhou Y; Zhu Z
    Front Immunol; 2021; 12():727254. PubMed ID: 34552590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increase of cells expressing PD-1 and PD-L1 and enhancement of IFN-γ production via PD-1/PD-L1 blockade in bovine mycoplasmosis.
    Goto S; Konnai S; Okagawa T; Nishimori A; Maekawa N; Gondaira S; Higuchi H; Koiwa M; Tajima M; Kohara J; Ogasawara S; Kato Y; Suzuki Y; Murata S; Ohashi K
    Immun Inflamm Dis; 2017 Sep; 5(3):355-363. PubMed ID: 28544524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blockade of the negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis.
    Chang KC; Burnham CA; Compton SM; Rasche DP; Mazuski RJ; McDonough JS; Unsinger J; Korman AJ; Green JM; Hotchkiss RS
    Crit Care; 2013 May; 17(3):R85. PubMed ID: 23663657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increase of cells expressing PD-L1 in bovine leukemia virus infection and enhancement of anti-viral immune responses in vitro via PD-L1 blockade.
    Ikebuchi R; Konnai S; Shirai T; Sunden Y; Murata S; Onuma M; Ohashi K
    Vet Res; 2011 Sep; 42(1):103. PubMed ID: 21943148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer.
    Zhang H; Dai Z; Wu W; Wang Z; Zhang N; Zhang L; Zeng WJ; Liu Z; Cheng Q
    J Exp Clin Cancer Res; 2021 Jun; 40(1):184. PubMed ID: 34088360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model.
    Yu P; Steel JC; Zhang M; Morris JC; Waitz R; Fasso M; Allison JP; Waldmann TA
    Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6187-92. PubMed ID: 22474386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitors of Cytotoxic T Lymphocyte Antigen 4 and Programmed Death 1/Programmed Death 1 Ligand for Metastatic Melanoma, Dual Versus Monotherapy-Summary of Advances and Future Directions for Studying These Drugs.
    Loo K; Daud AI
    Cancer J; 2017; 23(1):3-9. PubMed ID: 28114249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas.
    Kassardjian A; Shintaku PI; Moatamed NA
    PLoS One; 2018; 13(4):e0195958. PubMed ID: 29672601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model.
    Reardon DA; Gokhale PC; Klein SR; Ligon KL; Rodig SJ; Ramkissoon SH; Jones KL; Conway AS; Liao X; Zhou J; Wen PY; Van Den Abbeele AD; Hodi FS; Qin L; Kohl NE; Sharpe AH; Dranoff G; Freeman GJ
    Cancer Immunol Res; 2016 Feb; 4(2):124-35. PubMed ID: 26546453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma.
    Kroon P; Gadiot J; Peeters M; Gasparini A; Deken MA; Yagita H; Verheij M; Borst J; Blank CU; Verbrugge I
    Cancer Immunol Immunother; 2016 Jun; 65(6):753-63. PubMed ID: 27160390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a high-affinity anti-bovine PD-1 rabbit-bovine chimeric antibody using an efficient selection and large production system.
    Okagawa T; Konnai S; Goto S; Sajiki Y; Ganbaatar O; Watari K; Nakamura H; Wang CX; Tachibana T; Kato Y; Kameda Y; Kohara J; Terasaki N; Kubota M; Takeda A; Takahashi H; Suzuki Y; Maekawa N; Murata S; Ohashi K
    Vet Res; 2023 Sep; 54(1):82. PubMed ID: 37759311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer Stem Cell Vaccination With PD-L1 and CTLA-4 Blockades Enhances the Eradication of Melanoma Stem Cells in a Mouse Tumor Model.
    Zheng F; Dang J; Zhang H; Xu F; Ba D; Zhang B; Cheng F; Chang AE; Wicha MS; Li Q
    J Immunother; 2018 Oct; 41(8):361-368. PubMed ID: 30063587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.